SIV infection induces alterations in gene expression and loss of interneurons in Rhesus Macaque frontal cortex during early systemic infection
- PMID: 39890796
- PMCID: PMC11785960
- DOI: 10.1038/s41398-025-03261-2
SIV infection induces alterations in gene expression and loss of interneurons in Rhesus Macaque frontal cortex during early systemic infection
Abstract
Understanding the neurobiological mechanisms underlying HIV-associated neurocognitive decline in people living with HIV is frequently complicated by an inability to analyze changes across the course of the infection and frequent presence of comorbid psychiatric and substance use disorders. Preclinical non-human primate simian immunodeficiency virus (SIV) models help address these shortcomings. However, SIV studies frequently target protracted endpoints, limiting our understanding of the neuromolecular alterations during the early post-infection window. To begin to address this knowledge gap, we utilized single nuclei transcriptomics to examine frontal cortex samples of rhesus macaques 10- and 20-days post-SIV infection, compared to non-infected controls. We identify and validated a decrease in inhibitory neurons during the early post infection window, representing a potential substrate of longer-term injury and neurocognitive impairment in people living with HIV. Differential expression identified alterations in cellular subtype gene expression that persisted over the 20-day time course and short-lived differences only detected at 10-days post-SIV infection. In silico predicted regulatory mechanisms and dysregulated neural signaling pathways are presented. Analysis of cell-cell interaction networks identify altered signal pathways in the frontal cortex that may represent regional alterations in cell-cell communications. In total, these results identify cell type-specific molecular mechanisms putatively capable of underlying long-term neurocognitive alterations in persons living with HIV.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: BCR and MRH receive research funding from Novo Nordisk and Boehringer Ingelheim that was not used in support of these studies. BCR receives in-kind support from Oxford Nanopore Technologies and 10x Genomics were not used in support of these studies. MRH receives research funding from Eli Lilly & Co., Gila Therapeutics, and Pfizer that was not used in support of these studies. MRH is CEO of Cantius Therapeutics, LLC which pursues biological work unrelated to the current study. All other authors declare no competing interests.
Figures
References
MeSH terms
Grants and funding
- R01 DK115762/DK/NIDDK NIH HHS/United States
- R00 AG051764/AG/NIA NIH HHS/United States
- R01NS122570/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- P30 AI045008/AI/NIAID NIH HHS/United States
- P30MH097488/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- R01 AG060931/AG/NIA NIH HHS/United States
- R01DK115762/U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases)
- R01 NS122570/NS/NINDS NIH HHS/United States
- P30 MH097488/MH/NIMH NIH HHS/United States
- U01 MH121260/MH/NIMH NIH HHS/United States
- R01 MH118203/MH/NIMH NIH HHS/United States
- C06 OD026690/OD/NIH HHS/United States
- R01 MH096875/MH/NIMH NIH HHS/United States
- P40 OD012217/OD/NIH HHS/United States
- P30AI045008/U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous
